Puma Biotechnology, Inc. (PBYI) income statement
PBYINasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 14/3019% below fair value
$7.05−0.07 (-0.98%)
Close on Nov 20, 2026Market cap $363.92MP/E 13.6Yield –
Puma Biotechnology, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- 74.8%
- Operating margin
- 13.2%
- Net margin
- 11.6%
- Return on equity, FY2025
- 28.0%
Financial strength
- Current ratio
- 2.91
- Debt to equity
- 0.00
- Debt to assets
- 0.0%
- Cash to current liabilities
- 73.3%
Valuation
- P/E ratio
- 13.6
- Price to sales
- 1.57
- Price to book
- 2.63
- Dividend yield
- –
See a number that looks wrong?